Please provide your email address to receive an email when new articles are posted on . Semaglutide benefits were observed for adults with type 2 diabetes and chronic kidney disease whether or not ...
Please provide your email address to receive an email when new articles are posted on . Semaglutide lowered risk for kidney outcomes consistently across BMI subgroups in the FLOW trial. Body weight ...
New data from the landmark FLOW trial, which linked the glucagon peptide 1 (GLP-1) receptor agonist semaglutide with significant kidney outcomes in patients with type 2 diabetes (T2D) and chronic ...
Trials of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, are documenting its direct kidney effects and broad benefits for diabetic kidney disease.
The FLOW and SELECT trials demonstrated that semaglutide vs placebo significantly decreased the risk for a composite endpoint of adverse kidney events by 24% and 22%, respectively. Semaglutide reduces ...
Bagsværd, Denmark, 5 March 2024 – Novo Nordisk today announced the headline results from the kidney outcomes trial FLOW. The announcement today follows the decision to stop the trial early due to ...
Onlymyhealth on MSN
Signs you may have a kidney stone: Early symptoms you should never ignore
If you suddenly feel a sharp, stabbing pain in your side that radiates toward your groin, you might be dealing with a kidney ...
Know key warning signs of kidney and urinary issues, along with simple prevention tips and daily habits to maintain optimal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results